These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18424161)

  • 1. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.
    DeMarch Z; Giampà C; Patassini S; Bernardi G; Fusco FR
    Neurobiol Dis; 2008 Jun; 30(3):375-387. PubMed ID: 18424161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
    Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
    PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
    Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
    PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
    DeMarch Z; Giampà C; Patassini S; Martorana A; Bernardi G; Fusco FR
    Neurobiol Dis; 2007 Feb; 25(2):266-73. PubMed ID: 17184995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.
    Paldino E; Balducci C; La Vitola P; Artioli L; D'Angelo V; Giampà C; Artuso V; Forloni G; Fusco FR
    Mol Neurobiol; 2020 Apr; 57(4):1889-1903. PubMed ID: 31879858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.
    Fusco FR; Anzilotti S; Giampà C; Dato C; Laurenti D; Leuti A; Colucci D'Amato L; Perrone L; Bernardi G; Melone MA
    Neurobiol Dis; 2012 Apr; 46(1):225-33. PubMed ID: 22311347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
    Giampà C; Patassini S; Borreca A; Laurenti D; Marullo F; Bernardi G; Menniti FS; Fusco FR
    Neurobiol Dis; 2009 Jun; 34(3):450-6. PubMed ID: 19281846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Phosphodiesterases in Huntington's Disease.
    Fusco FR; Paldino E
    Adv Neurobiol; 2017; 17():285-304. PubMed ID: 28956337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.
    Hansson O; Guatteo E; Mercuri NB; Bernardi G; Li XJ; Castilho RF; Brundin P
    Eur J Neurosci; 2001 Nov; 14(9):1492-504. PubMed ID: 11722611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.